Check out the latest #TAPUR study paper in #JCOPO: Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Read the full article: https://bit.ly/4cVvaUU
#ASCOConnection covers a new special series in #JCOCCI that explores the practical application of large language models (LLMs) and their impact on #CancerCare delivery.
Read more: connection.asco.org/do/navigating-opportunit...
#LLM
JCO Precision Oncology would like to welcome our newest Associate Editor Matthew B. Yurgelun, MD, of Dana-Farber Cancer Institute, Boston, Mass.
#JCOPO @mattyurgelun.bsky.social
PREDICT trial in #mCRPC takes precision onc a step further, integrating DNA + RNA profiling, molecular tumor boards & adaptive Tx allocation. Importantly, pts can be re-assigned at progression based on updated tumor biology--a move toward truly dynamic cancer care. Read more: https://bit.ly/4sZA8FH
#JCO welcomes as our newest Associate Editor Dr. Brigette Ma at the Prince of Wales Hospital, The Chinese University of Hong Kong. Welcome, Dr. Ma!
A new original report in #JCOPO provides valuables insights into the genomic landscape and prognostic biomarkers of advanced ESCC, which can guide future research toward more reliable biomarkers and targeted strategies.
Read the article: https://ascopubs.org/doi/10.1200/PO-25-00971
#esocsm
JCO Global Oncology welcomes new Associate Editor Haneen Abaza, MSc, ACRP-CP, from King Hussein Cancer Center!
The Art of Global Oncology series in #JCOGO provides a vital space for narratives that focus on the experience of living with cancer and caring for patients with cancer. Check out the latest Art of Global Oncology paper, "Maps, Scars, and the Miles Between": https://bit.ly/47uZlz9
We are proud to introduce our latest collection, Special Series: Large Language Models. The papers in this series discuss the practical application of LLMs, their impact on cancer care delivery, and the ethical & practical implications of these AI systems: https://bit.ly/4upseqn
JCO is seeking a clinical investigator and leader to serve as its next Editor-in-Chief. Submit your interest today to advance @ASCO’s flagship & highly cited publication. Interest forms due March 9. Apply: https://bit.ly/3ZyIzuF
JCO is seeking a clinical investigator and leader to serve as its next Editor-in-Chief. Submit your interest today to advance ASCO’s flagship & highly cited publication.
Submit your interest today: app.smartsheet.com/b/form/2448e4c7b7c34af69...
‼️#GU26 simultaneous publication by @AarmstrongDuke et al:
Trial Design and Objectives for Patients with Prostate Cancer: Recommendations From Prostate Cancer Working Group 4
Learn more: https://bit.ly/46dupmq
We are proud to name Zsofia Stadler, MD from
@mskcancercenter.bsky.social the next Editor-in-Chief of JCO Precision Oncology starting July 1st. Dr. Stadler’s expertise will drive the integration of genomics & AI into cancer research for improved patient outcomes. Read more: bit.ly/4aoLPyZ
#JCOPO
Dr. Pedro Barata of University Hospitals Seidman Cancer Center and Dr. Ugwuji Maduekwe of the Medical College of Wisconsin discuss the emergence of organ preservation in GEJ and gastric cancers on the latest episode of the ASCO Education #BytheBook Podcast.
Listen here: https://bit.ly/4tAUje4
JCO Global Oncology (JCO GO) guest editors Drs. Fabio Ynoe de Moraes & Paul Pearlman discuss JCO GO's Special Series featuring the investigators working to develop a new generation of innovations through the NCI’s Affordable Cancer Technologies Program.
Read more: https://bit.ly/4tr3vl9
The draft guideline update for "Breast Cancer Follow-Up After Primary Treatment" is now available. Help us refine these standards of care. Submit your feedback to @ascocancer.bsky.social by February 23!
Read & comment here: https://bit.ly/4ccwl2h
#bcsm #BreastCancer
Big news! Onyinye D. Balogun, MD, MSc joins JCO Global Oncology as the new Associate Editor!
We’re excited to have her expertise from @northwellhealth.bsky.social. Welcome, Dr. Balogun!
#JCOGO #GlobalOncology
We are thrilled to announce that Dr. Chiara Cremolini is joining the Journal of Clinical Oncology (JCO) as our newest Associate Editor!
Her expertise in colorectal oncology & clinical and translational research aligns perfectly with our mission to advance cancer care.
New #ASCO #JCO Cancer Stories: "A Chance to Heal with Cold Hard Steel" with host @mikkaelsekeres.bsky.social. Dr. Taylor Goodstein shares a powerful perspective on surgery, grief, and finding courage within our own fallibility.
Tune in: https://bit.ly/4rG0nQL
JCO Updated Stage IV NSCLC guidelines:
➡️ASCO Living Guideline: Stage IV NSCLC (With Drivers) https://bit.ly/49SWlye
➡️ASCO Living Guideline: Stage IV NSCLC (Without Drivers) https://bit.ly/4at28L1
Exciting news! Fabio Ynoe de Moraes, MD, PhD, MBA, of Queen’s University has been named Deputy Editor of JCO Global Oncology.
Dr. Moraes’ leadership will drive #JCOGO’s mission to improve cancer care access and equity worldwide.
Join us in congratulating Dr. Moraes!
#GlobalOncology
#Telehealth has been a huge boon to oncology: save pts time, see people who might not be able to travel.
Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts?
A: Largely, no! Similar communication, slight ⬆️ appts.
ascopubs.org/doi/full/10....
We are thrilled to welcome Dr. Hsu as the new Editor-in-Chief of the ASCO Educational Book. A leader at UCSF and the San Francisco VA, Dr. Hsu aims to evolve the journal by embracing new formats to contextualize emerging oncology discoveries. Welcome!
In the latest #JCO Cancer Stories with host Dr. @mikkaelsekeres.bsky.social
Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children.
Listen here: https://bit.ly/3ZxVYD9
#ArtOfOncology
When an oncologist leaves a rural community, the vacancy is more than a line item on a HR report. A new #JCOOP study explores the repercussions of specialist scarcity.
Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...
New @ascocancer.bsky.social mCRPC living guideline updated recommendations for systemic therapy are here! For patients w/ visceral metastases (lung/liver), enzalutamide or docetaxel is advised, regardless of HRR status.
Stay current on mCRPC care: brnw.ch/21wZfuI
Check out JCO Precision Oncology's new TAPUR Study Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry. Learn more: brnw.ch/21wZ9I0
Here is our publication in @jco-asco.bsky.social! We describe how common medications impact immunotherapy, how this affects practice and patients today, and outline ways to leverage this knowledge toward improved patient as well as our understanding of tumor immunology.
ascopubs.org/doi/10.1200/...
Attending ASCO #GI26? Join the Pathways to Publication Luncheon to meet the JCO Journals editorial team.
Get tips on peer review & publishing your manuscript. Limited space—first come, first served!
📅 Jan 9 | 11:45 AM PT | Level 3, Room 3005
Just published in #JCO, @jmikhaelmd.bsky.social & @lisakhicks.bsky.social introduce a new @ascocancer.bsky.social living guideline w/ updated recommendations for multiple myeloma therapy in differing variants and pt populations.
Learn more: brnw.ch/21wYSoe
